Compugen | BiotechTV

top of page

Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs

The company's new CEO Eran Ophir discusses the computational work that when into Compugen's understanding of TIGIT biology, and he walks us through their partnership with AstraZeneca. Plus, recent ESMO data for PVRIG and a trial in progress for IL18BP.

Company News

21 hours ago

SITC 2024: Compugen's CEO discusses ovarian cancer data for her company's TIGIT + PVRIG + pembro triplet combo

Anat Cohen-Dayag describes this SITC data, shares her opinion on the TIGIT field, and highlights an IL-18 program that is partnered with...

Company News

Nov 9, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs

SITC 2024: Compugen's CEO discusses ovarian cancer data for her company's TIGIT + PVRIG + pembro triplet combo

Follow BiotechTV

Sponsors

Sponsor Spotlight